Recognizing the Need for Oncology Education in Canadian Baccalaureate Nursing Programs.

There is a critical need for quality oncology education in Canadian baccalaureate nursing programs considering the vast amount of cancer diagnoses and deaths in the Canadian population, as well as the likelihood that all nurses will care for oncology patients in various settings. The incidence and mortality of cancer within the Canadian population impact the need to incorporate an all-inclusive view of cancer care into baccalaureate nursing curriculums and develop nurse leaders in oncology at this level. Currently, Canadian nursing programs are generalist programs and provide little oncology content especially in the clinical setting.

Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.

Metronomic, low dose chemotherapy may have anti-angiogenic effects and augment the effects of lenalidomide in MDS and CMML. We evaluated the clinical efficacy, tolerability and anti-angiogenic effects of melphalan 2mg and lenalidomide 10mg for 21 days/28 in CMML (n=12) and higher risk MDS (n=8) patients in a prospective phase II study. The primary endpoint was overall response and secondary endpoints included survival, progression-free survival, toxicity and biomarkers of angiogenesis.